Carla L Alves
7PUBLICATIONS
14CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Dec 17, 2025
Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer.Carla L Alves, Leena Karimi, Mikkel G Terp
|Jul 25, 2025
Deciphering Breast Tumor Heterogeneity Through Patient-Derived Organoids and Circulating Tumor Cells.Benedetta Policastro, Nikoline Nissen, Carla L Alves
|Sep 17, 2021
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.Carla L Alves, Sidse Ehmsen, Mikkel G Terp
|Aug 26, 2021
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.Carla L Alves, Sidse Ehmsen, Mikkel G Terp
|Jan 05, 2021
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.Sanne Løkkegaard, Daniel Elias, Carla L Alves
Pageof 2
Frequent Collaborators
6 joint publications
Henrik J Ditzel
3 joint publications
Martin Bak
3 joint publications
Elgene Lim
2 joint publications
Sidse Ehmsen
2 joint publications
Martina Tuttolomondo
2 joint publications
Odd L Gammelgaard
2 joint publications
Benedetta Policastro
1 joint publications
Laura J Esserman
1 joint publications
Jens S Andersen
1 joint publications
Leena Karimi
